News

The company has expanded the team based out of Oxford and expanded clinical data management services to the UK. PSI UK head Sarah Eastty said, "We are pleased

According to the deal, Stendhal is responsible for regulatory/clinical development and commercialization activites of the phase III ghrelin receptor agonist in Mexico, Venezuela, Colombia, Peru, Ecuador and many

According to the renewed deal, Novamed Pharmaceuticals, a wholly owned subsidiary of SciClone, will promote the products in the region till 31 December 2013 with a possibility of

Under the deals, Oxford will have access to Lophius’ UREA technology while Lophius will gain access to Oxford’s T-SPOT technology. Oxford chief executive officer Dr. Peter Wrighton-Smith said,

Caldolor (ibuprofen) Injection, which features analgesic, antipyretic and anti-inflammatory properties, is indicated for pain and fever in the hospital setting. Cumberland Pharmaceuticals chief executive officer A.J. Kazimi said,

Minivelle, which the company claims is the smallest estrogen patch, is bioequivalent to company’s Vivelle, (estradiol transdermal system) and is 34% smaller than Vivelle-Dot. The company said Minivelle,

Total revenue for fourth quarter of 2012 was $5.96bn compared to $6.05bn for the fourth quarter of 2011. The company reported a net income of $4.09bn, or $3.66

The JV will formulate Leuprolide in a proprietary controlled-release drug delivery platform technology, developed by Foresee. Under the JV, ScinoPharm will act as the exclusive provider of Leuprolide

Under the deal, Afraxis will earn around $187.5m in total as upfront, research, development and commercialization milestone payments. Afraxis president and CEO and Avalon Ventures managing partner Jay